The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL

Author： Carinci Francesco  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.2, 2012-04, pp. : 810-818

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases

By  

Current Drug Targets, Vol. 13, Iss. 9, 2012-08 ,pp. : 1215-1221

Bentham Science Publishers

Access to resources Recommend Favorite

TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases

By  

Current Drug Targets, Vol. 13, Iss. 8, 2012-07 ,pp. : 1089-1095

Bentham Science Publishers

Access to resources Recommend Favorite

TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential

By  

Current Pharmaceutical Design, Vol. 11, Iss. 7, 2005-03 ,pp. : 933-944

Bentham Science Publishers

Access to resources Recommend Favorite

TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies

By  

Current Medicinal Chemistry, Vol. 20, Iss. 17, 2013-06 ,pp. : 2254-2271

Bentham Science Publishers

Access to resources Recommend Favorite

Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus

By  

Current Pharmaceutical Design, Vol. 18, Iss. 35, 2012-12 ,pp. : 5759-5765

Bentham Science Publishers

Access to resources Recommend Favorite